Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.15 USD | -0.49% | -8.70% | -12.14% |
May. 17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
May. 14 | KALA BIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 17.41M |
---|---|---|---|---|---|
Net income 2024 * | -50M | Net income 2025 * | -47M | EV / Sales 2024 * | - |
Net Debt 2024 * | 2.46M | Net cash position 2025 * | 39.69M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.42
x | P/E ratio 2025 * |
-0.64
x | Employees | 43 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.71% |
1 day | -0.49% | ||
1 week | -8.70% | ||
Current month | -8.48% | ||
1 month | -10.87% | ||
3 months | -21.36% | ||
6 months | -15.06% | ||
Current year | -12.14% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Iwicki
CEO | Chief Executive Officer | 57 | 15-02-28 |
Mary Reumuth
DFI | Director of Finance/CFO | 48 | 14-01-31 |
Todd Bazemore
PSD | President | 53 | 17-11-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Koven
BRD | Director/Board Member | 66 | 17-09-27 |
Gregory Perry
BRD | Director/Board Member | 63 | 18-03-04 |
Howard Rosen
BRD | Director/Board Member | 66 | 14-01-05 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 6.15 | -0.49% | 31,584 |
24-06-11 | 6.18 | -0.48% | 5,647 |
24-06-10 | 6.21 | -5.48% | 21,389 |
24-06-07 | 6.57 | 0.00% | 3,832 |
24-06-06 | 6.57 | -3.81% | 8,469 |
Delayed Quote Nasdaq, June 12, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.14% | 17.41M | |
+48.79% | 780B | |
+41.76% | 627B | |
+19.43% | 334B | |
+7.18% | 296B | |
+17.60% | 244B | |
-0.41% | 217B | |
+11.54% | 214B | |
+4.53% | 161B | |
-3.92% | 159B |
- Stock Market
- Equities
- KALA Stock